Bioventix plc
(“Bioventix” or the “Company”)
Director/PDMR
Shareholding
Bioventix plc (BVXP), a UK company specialising in the
development and commercial supply of high-affinity monoclonal
antibodies for applications in clinical diagnostics, announces that
it has been notified that Peter
Harrison, Chief Executive, has dealt in the Ordinary Shares
of 5 pence each (the “Ordinary
Shares”) as follows:
- On 1 April 2020, the sale of
30,000 Ordinary Shares at 3,600 pence
per Ordinary Share (the “Sale”); and
- On 2 April 2020, the exercise of
options over 18,500 Ordinary Shares at 1,350
pence per Ordinary Share (the “Option Shares”), pursuant to
the Company’s 2013 EMI Share Option Scheme (the “Exercise”)
(details of which can be found at www.bioventix.com).
Following the Sale and the Exercise, Peter Harrison’s total
beneficial interest in the Company will be 416,676 Ordinary Shares
representing approximately 8.0% of the Company.
Following the Exercise, the Company has applied for 18,500
Ordinary Shares to be admitted to trading on AIM (“Admission”). It
is expected that Admission will occur and that dealings will
commence in the Option Shares on 8 April
2020. The Option Shares will rank pari passu with the
existing Ordinary Shares.
The total number of Ordinary Shares in issue following Admission
will be 5,207,835 and the Company holds no shares in treasury.
Therefore, the total number of Ordinary Shares with voting rights
in the Company will be 5,207,835.
The above figure of 5,207,835 may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, Bioventix under the FCA’s Disclosure Guidance and
Transparency Rules.
For further information please
contact:
Bioventix
plc
Peter Harrison |
Chief Executive Officer |
Tel: 01252 728 001 |
|
|
|
finnCap Ltd
Geoff Nash/Simon Hicks
Alice Lane |
Corporate Finance
ECM |
Tel: 020 7220 0500 |
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and
commercial supply of high-affinity monoclonal antibodies with a
primary focus on their application in clinical diagnostics, such as
in automated immunoassays used in blood testing. The antibodies
created at Bioventix are generated in sheep and are of particular
benefit where the target is present at low concentration and where
conventional monoclonal or polyclonal antibodies have failed to
produce a suitable reagent. Bioventix currently offers a portfolio
of antibodies to customers for both commercial use and R&D
purposes, for the diagnosis or monitoring of a broad range of
conditions, including heart disease, cancer, fertility, thyroid
function and drug abuse. Bioventix currently supplies antibody
products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its
shares are traded on AIM under the symbol BVXP.
| 1 |
Details of the person
discharging managerial responsibilities (“PDMR”) / person closely
associated (“PCA”) |
| a) |
Name |
Peter Harrison |
| 2. |
Reason for the
Notification |
| a) |
Position/status |
Chief Executive Officer |
| b) |
Initial notification/Amendment |
Initial notification |
| 3. |
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor |
| a) |
Name |
Bioventix plc |
| b) |
LEI |
213800225MHX7LZQY108 |
| 4. |
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
| a) |
Description of the Financial
instrument, type of instrument |
Ordinary Shares of 5 pence each |
| Identification code |
GB00B4QVDF07 |
| b) |
Nature of the transaction |
Sale of Ordinary Shares |
| c) |
Price(s) and volume(s) |
| Price(s) |
Volume(s) |
| 3,600p |
30,000 |
|
| d) |
Aggregated
information:
· Aggregated volume
· Price |
30,000
3,600p |
| e) |
Date of the transaction |
1 April 2020 |
| f) |
Place of the transaction |
London Stock Exchange, AIM Market
(XLON) |
| 1 |
Details of the person
discharging managerial responsibilities (“PDMR”) / person closely
associated (“PCA”) |
| a) |
Name |
Peter Harrison |
| 2. |
Reason for the
Notification |
| a) |
Position/status |
Chief Executive Officer |
| b) |
Initial notification/Amendment |
Initial notification |
| 3. |
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor |
| a) |
Name |
Bioventix plc |
| b) |
LEI |
213800225MHX7LZQY108 |
| 4. |
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
| a) |
Description of the Financial
instrument, type of instrument |
Options over Ordinary Shares of 5
pence each |
| Identification code |
GB00B4QVDF07 |
| b) |
Nature of the transaction |
Exercise of Options |
| c) |
Price(s) and volume(s) |
| Price(s) |
Volume(s) |
| 1,350p |
18,500 |
|
| d) |
Aggregated
information:
· Aggregated volume
· Price |
18,500
1,350p |
| e) |
Date of the transaction |
2 April 2020 |
| f) |
Place of the transaction |
London Stock Exchange, AIM Market
(XLON) |